Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 30, 2018 in Overactive bladder | 0 comments

In a nutshell

This study aimed to investigate the efficacy of a new drug, vibegron (Beova), on nocturia in patients with overactive bladder (OAB). This study found that vibegron is a useful option to improve nocturia in these patients.

Some background

Overactive bladder (OAB) occurs when the bladder muscle is too active. Instead of staying at rest as urine fills the bladder, the bladder contracts. This causes a person to feel a sudden and sometimes overwhelming urge to urinate even when the bladder is not full. Nocturia (getting up to urinate during the night) can also occur in patients with OAB. One treatment that is being developed for OAB is vibegron. The effectiveness of vibegron in patients with OAB and nocturia are still unclear. 

Methods & findings

This study included 669 patients with OAB. Patients were given vibegron at a high (100mg; 218 patients) or low dose (50mg; 227 patients). The other 224 patients had a placebo. Patients filled out questionnaires to assess their level of nocturia and impact on their quality of life. The patients were evaluated at the beginning of the study and after 12 weeks o treatment. 

Nocturia was significantly improved for patients on vibegron compared to patients taking a placebo 12 weeks after starting the study. Patients who took vibegron had more hours of uninterrupted sleep. 

The bottom line

This study found that vibegron is a useful option to improve nocturia in patients with OAB.

The fine print

This study was funded by Kyorin Pharmaceuticals, the developer of vibegron.

Published By :

International journal of urology: official journal of the Japanese Urological Association

Date :

Dec 17, 2018

Original Title :

Efficacy of novel β3 -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.

click here to get personalized updates